Patent US5500555A successfully refreshed from Google Patents.
US4551473A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting snoring and obstructive sleep apnea
Assignee: Individual
•
Filing: 1984-04-26
•
Granted: 1985-11-05
•
Expires: 2004-04-26
Abstract
Abstract Snoring and obstructive sleep apnea are relieved in most instances by administering an effective dose of a muscle relaxant that acts at the spinal or supra-spinal level. A presently preferred drug is orphenadrine citrate.
Inventors
- 👤 George W. Schossow
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 08:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/42; A61K31/13; A61K31/135; A61K31/185; A61K31/19; A61K31/195; A61K31/435; A61K31/47; A61K31/49
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
26 words
A method of inhibiting or preventing snoring and associated obstructive sleep apnea comprising administering to a person displaying such symptoms an effective amount of orphenadrine citrate.
Claim 2
Independent Claim
26 words
A method of inhibiting or preventing snoring and associated obstructive sleep apnea comprising administering to a person displaying such symptoms an effective amount of orphenadrine citrate.
Claim 3
Dependent Claim
23 words
The method of claim 1 wherein the muscle relaxant is administered in an amount of about 50-300 mg prior to the patient's retiring.
Claim 4
Independent Claim
51 words
A method of inhibiting or preventing snoring and associated abstructive sleep apnea comprising administering to a person displaying such symptoms an effective amount of muscle relaxant acting at the spinal or supra-spinal level and selected from the class consisting of orphenadrine, orphenadrine citrate, 4-amino-3(p-chlorophenyl butyric acid), quinine sulfate and 5-chloro benzoxazolinone.
Claim 5
Independent Claim
51 words
A method of inhibiting or preventing snoring and associated abstructive sleep apnea comprising administering to a person displaying such symptoms an effective amount of muscle relaxant acting at the spinal or supra-spinal level and selected from the class consisting of orphenadrine, orphenadrine citrate, 4-amino-3(p-chlorophenyl butyric acid), quinine sulfate and 5-chloro benzoxazolinone.
References Cited (Backward Citations)
US2991225A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-11-04 | 1989-05-06 | 1989-11-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-11-04 | 1993-05-06 | 1993-11-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-11-04 | 1997-05-06 | 1997-11-05 | $7700.00 | Window Closed / Lapsed |